Inflammation-Targeted Nanomedicines for the Treatment of Chronic Inflammatory Diseases and Cancer
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 107
Special Issue Editors
2. UNIPRO—Unidade de Investigação em Patologia e Reabilitação Oral, Instituto Universitário de Ciências da Saúde (IUCS-CESPU), 4585-116 Gandra, Portugal
3. i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
Interests: drug delivery; inflammatory bowel disease; mucosal drug delivery; mucus penetrating nanoparticles; nanomedicine; smart nanosystems
Special Issue Information
Dear Colleagues,
Chronic inflammation is a key driver of numerous debilitating conditions, including inflammatory bowel disease, rheumatoid arthritis, chronic respiratory disorders, neurodegenerative diseases, and cardiovascular disease. Moreover, it plays a critical role in the development and progression of various cancers. The global incidence of chronic inflammatory disorders is rising, driven by increased life expectancy and population ageing as well as societal development and the interplay between genetic and environmental factors. Furthermore, the large socio-economic impact of chronic inflammation-driven disorders carries significant implications for both patients and society, demanding novel and comprehensive strategies to mitigate the consequences of chronic inflammation. Recent advances in nanomedicine have enabled the development of targeted, sustained, and responsive therapeutic platforms with the potential to overcome the limitations of conventional treatments. This Pharmaceutics Special Issue is dedicated to exploring nanotechnology-based delivery systems targeting the inflammatory niche that characterizes chronic inflammatory diseases and cancer.
As Guest Editors, we would like to encourage colleagues to submit their research work in the format of full papers or pertinent reviews, from diverse fields such as immunology, oncology, pharmaceutical sciences, nanomedicine and regenerative medicine, to develop innovative research that advances the clinical translation of next-generation therapies for chronic inflammatory disorders and cancer. We look forward to your contributions.
Dr. Rute Nunes
Dr. Flávia Castro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- atherosclerosis
- cancer
- chronic inflammation
- chronic respiratory diseases
- diabetes
- immunomodulation
- inflammation-responsive drug delivery systems
- inflammatory bowel disease
- multiple sclerosis
- nanomedicine
- novel biomaterials
- rheumatoid arthritis
- targeted drug delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
